Canaccord Genuity Maintains Buy on Helus Pharma, Raises Price Target to $58
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $42 to $58.
Follow the latest Helus Pharma Inc. (HELP) news and market headlines alongside the live HELP price. Stay informed on what's moving HELP.
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $42 to $58.
Helus Pharma reports positive Phase 3 data as adjunctive depression drug HLP003 rapidly reduces symptoms through 12 weeks in adult patients.
U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(0.64) by 120.31 percent. This is a 1.44 percent decrease over losses of $(1.39) per share from
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) ("Helus Pharma" or the "Company"), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health conditions
Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.
Helus Pharma announced it will present topline results from its Phase 3 APPROACH study evaluating HLP003 for major depressive disorder on November 16, 2026. HLP003, a novel serotonergic agonist, has received FDA Breakthrough Therapy Designation. The company is also developing HLP004 for generalized anxiety disorder in Phase 2 trials.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to HELP, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.